Living Cell faces slower road to commercialisation after trial needs more analysis

ASX-listed Kiwi biotech firm Living Cell Technologies won’t seek provisional consent for its treatment for Parkinson’s disease after the latest trial did not show a “statistically significant difference” between people who received…

Leave a Reply